Analysis of Short-term (Operating) Activity Ratios
Quarterly Data
Beginner level
Activity ratios measure how efficiently a company performs day-to-day tasks, such us the collection of receivables and management of inventory.
Short-term Activity Ratios (Summary)
Gilead Sciences Inc., short-term (operating) activity ratios (quarterly data)
Based on: 10-Q (filing date: 2020-08-06), 10-Q (filing date: 2020-05-06), 10-K (filing date: 2020-02-25), 10-Q (filing date: 2019-11-05), 10-Q (filing date: 2019-08-06), 10-Q (filing date: 2019-05-08), 10-K (filing date: 2019-02-26), 10-Q (filing date: 2018-11-06), 10-Q (filing date: 2018-08-06), 10-Q (filing date: 2018-05-09), 10-K (filing date: 2018-02-27), 10-Q (filing date: 2017-11-07), 10-Q (filing date: 2017-08-07), 10-Q (filing date: 2017-05-10), 10-K (filing date: 2017-02-27), 10-Q (filing date: 2016-11-07), 10-Q (filing date: 2016-08-05), 10-Q (filing date: 2016-05-06), 10-K (filing date: 2016-02-24), 10-Q (filing date: 2015-11-04), 10-Q (filing date: 2015-08-05), 10-Q (filing date: 2015-05-08).
| Short-term activity ratio | Description | The company |
|---|---|---|
| Inventory turnover | An activity ratio calculated as cost of goods sold divided by inventory. | Gilead Sciences Inc.’s inventory turnover ratio deteriorated from Q4 2019 to Q1 2020 and from Q1 2020 to Q2 2020. |
| Receivables turnover | An activity ratio equal to revenue divided by receivables. | Gilead Sciences Inc.’s receivables turnover ratio deteriorated from Q4 2019 to Q1 2020 but then improved from Q1 2020 to Q2 2020 exceeding Q4 2019 level. |
| Payables turnover | An activity ratio calculated as cost of goods sold divided by payables. | Gilead Sciences Inc.’s payables turnover ratio increased from Q4 2019 to Q1 2020 and from Q1 2020 to Q2 2020. |
| Working capital turnover | An activity ratio calculated as revenue divided by working capital. | Gilead Sciences Inc.’s working capital turnover ratio improved from Q4 2019 to Q1 2020 and from Q1 2020 to Q2 2020. |
| Short-term activity ratio | Description | The company |
|---|---|---|
| Average inventory processing period | An activity ratio equal to the number of days in the period divided by inventory turnover over the period. | Gilead Sciences Inc.’s number of days of inventory outstanding deteriorated from Q4 2019 to Q1 2020 and from Q1 2020 to Q2 2020. |
| Average receivable collection period | An activity ratio equal to the number of days in the period divided by receivables turnover. | Gilead Sciences Inc.’s number of days of receivables outstanding deteriorated from Q4 2019 to Q1 2020 but then improved from Q1 2020 to Q2 2020 exceeding Q4 2019 level. |
| Operating cycle | Equal to average inventory processing period plus average receivables collection period. | Gilead Sciences Inc.’s operating cycle deteriorated from Q4 2019 to Q1 2020 but then improved from Q1 2020 to Q2 2020 not reaching Q4 2019 level. |
| Average payables payment period | An estimate of the average number of days it takes a company to pay its suppliers; equal to the number of days in the period divided by payables turnover ratio for the period. | Gilead Sciences Inc.’s number of days of payables outstanding decreased from Q4 2019 to Q1 2020 and from Q1 2020 to Q2 2020. |
| Cash conversion cycle | A financial metric that measures the length of time required for a company to convert cash invested in its operations to cash received as a result of its operations; equal to average inventory processing period plus average receivables collection period minus average payables payment period. | Gilead Sciences Inc.’s cash conversion cycle deteriorated from Q4 2019 to Q1 2020 but then slightly improved from Q1 2020 to Q2 2020. |
Inventory Turnover
Gilead Sciences Inc., inventory turnover calculation (quarterly data)
| Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||||||
| Cost of goods sold | 1,064 | 969 | 1,683 | 1,035 | 1,000 | 957 | 1,570 | 1,086 | 1,196 | 1,001 | 1,256 | 1,032 | 1,126 | 957 | 1,075 | 1,129 | 864 | 1,193 | 1,062 | 1,064 | 998 | 882 | |||||||
| Inventories | 1,052 | 986 | 922 | 882 | 884 | 898 | 814 | 816 | 859 | 885 | 801 | 1,144 | 1,408 | 1,474 | 1,587 | 1,900 | 1,862 | 1,880 | 1,955 | 1,988 | 2,039 | 1,908 | |||||||
| Short-term Activity Ratio | |||||||||||||||||||||||||||||
| Inventory turnover1 | 4.52 | 4.75 | 5.07 | 5.17 | 5.22 | 5.36 | 5.96 | 5.56 | 5.22 | 4.99 | 5.46 | 3.66 | 3.04 | 2.73 | 2.68 | 2.24 | 2.25 | 2.30 | 2.05 | — | — | — | |||||||
| Benchmarks | |||||||||||||||||||||||||||||
| Inventory Turnover, Competitors2 | |||||||||||||||||||||||||||||
| Abbott Laboratories | 2.56 | 2.92 | 3.07 | 2.96 | 2.94 | 3.13 | 3.35 | 3.38 | 3.36 | 3.23 | 3.43 | 3.27 | 3.00 | 2.49 | 3.71 | 3.41 | 3.15 | 3.16 | 3.37 | — | — | — | |||||||
| AbbVie Inc. | 2.36 | 4.17 | 4.10 | 3.86 | 3.89 | 4.40 | 4.81 | 4.47 | 4.91 | 4.23 | 4.39 | 3.54 | 3.92 | 4.26 | 4.04 | 3.53 | 3.08 | 2.75 | 2.62 | — | — | — | |||||||
| Amgen Inc. | 1.38 | 1.31 | 1.22 | 1.29 | 1.32 | 1.40 | 1.39 | 1.35 | 1.31 | 1.36 | 1.44 | 1.39 | 1.39 | 1.44 | 1.52 | 1.55 | 1.56 | 1.64 | 1.74 | — | — | — | |||||||
| Biogen Inc. | 1.83 | 2.10 | 2.43 | 2.66 | 2.61 | 2.56 | 1.95 | 2.00 | 1.87 | 1.90 | 1.81 | 1.49 | 1.65 | 1.68 | 1.48 | 1.42 | 1.33 | 1.29 | 1.39 | — | — | — | |||||||
| Bristol-Myers Squibb Co. | 4.45 | 3.49 | 1.88 | 6.15 | 5.48 | 5.31 | 5.48 | 5.09 | 5.20 | 5.19 | 5.20 | 4.62 | 4.53 | 3.72 | 3.99 | 3.05 | 3.00 | 3.08 | 3.20 | — | — | — | |||||||
| Eli Lilly & Co. | 1.48 | 1.55 | 1.48 | 1.62 | 1.70 | 1.96 | 1.56 | 1.57 | 1.56 | 1.36 | 1.36 | 1.34 | 1.32 | 1.40 | 1.59 | 1.44 | 1.44 | 1.38 | 1.46 | — | — | — | |||||||
| Illumina Inc. | 2.29 | 2.74 | 3.00 | 2.55 | 2.53 | 2.55 | 2.68 | 2.65 | 2.67 | 2.69 | 2.78 | 2.72 | 2.71 | 2.63 | 2.44 | 2.28 | 2.23 | 2.37 | 2.48 | — | — | — | |||||||
| Johnson & Johnson | 2.93 | 3.16 | 3.05 | 2.99 | 2.93 | 2.98 | 3.15 | 3.15 | 3.14 | 2.95 | 2.89 | 2.48 | 2.29 | 2.45 | 2.66 | 2.57 | 2.53 | 2.64 | 2.67 | — | — | — | |||||||
| Merck & Co. Inc. | 2.33 | 2.46 | 2.36 | 2.35 | 2.29 | 2.34 | 2.48 | 2.52 | 2.56 | 2.41 | 2.51 | 2.41 | 2.37 | 2.59 | 2.85 | 2.75 | 2.81 | 2.93 | 3.18 | — | — | — | |||||||
| Pfizer Inc. | 1.15 | 1.21 | 1.23 | 1.30 | 1.31 | 1.38 | 1.50 | 1.40 | 1.43 | 1.39 | 1.48 | 1.41 | 1.51 | 1.61 | 1.82 | 1.67 | 1.53 | 1.41 | 1.28 | — | — | — | |||||||
| Regeneron Pharmaceuticals Inc. | 0.25 | 0.25 | 0.26 | 0.22 | 0.16 | 0.15 | 0.16 | 0.18 | 0.22 | 0.26 | 0.28 | 0.30 | 0.32 | 0.38 | 0.49 | 0.64 | 0.82 | 0.92 | 1.01 | — | — | — | |||||||
| Vertex Pharmaceuticals Inc. | 3.03 | 3.29 | 3.27 | 2.99 | 3.25 | 3.17 | 3.29 | 2.99 | 2.89 | 2.55 | 2.46 | 2.56 | 2.52 | 2.52 | 2.71 | 2.97 | 2.87 | 2.58 | 2.18 | — | — | — | |||||||
| Zoetis Inc. | 1.21 | 1.31 | 1.41 | 1.39 | 1.42 | 1.46 | 1.37 | 1.27 | 1.26 | 1.23 | 1.24 | 1.20 | 1.18 | 1.12 | 1.11 | 1.08 | 1.12 | 1.19 | 1.18 | — | — | — | |||||||
Based on: 10-Q (filing date: 2020-08-06), 10-Q (filing date: 2020-05-06), 10-K (filing date: 2020-02-25), 10-Q (filing date: 2019-11-05), 10-Q (filing date: 2019-08-06), 10-Q (filing date: 2019-05-08), 10-K (filing date: 2019-02-26), 10-Q (filing date: 2018-11-06), 10-Q (filing date: 2018-08-06), 10-Q (filing date: 2018-05-09), 10-K (filing date: 2018-02-27), 10-Q (filing date: 2017-11-07), 10-Q (filing date: 2017-08-07), 10-Q (filing date: 2017-05-10), 10-K (filing date: 2017-02-27), 10-Q (filing date: 2016-11-07), 10-Q (filing date: 2016-08-05), 10-Q (filing date: 2016-05-06), 10-K (filing date: 2016-02-24), 10-Q (filing date: 2015-11-04), 10-Q (filing date: 2015-08-05), 10-Q (filing date: 2015-05-08).
1 Q2 2020 Calculation
Inventory turnover
= (Cost of goods soldQ2 2020
+ Cost of goods soldQ1 2020
+ Cost of goods soldQ4 2019
+ Cost of goods soldQ3 2019)
÷ Inventories
= (1,064 + 969 + 1,683 + 1,035)
÷ 1,052 = 4.52
2 Click competitor name to see calculations.
| Short-term activity ratio | Description | The company |
|---|---|---|
| Inventory turnover | An activity ratio calculated as cost of goods sold divided by inventory. | Gilead Sciences Inc.’s inventory turnover ratio deteriorated from Q4 2019 to Q1 2020 and from Q1 2020 to Q2 2020. |
Receivables Turnover
Gilead Sciences Inc., receivables turnover calculation (quarterly data)
| Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||||||
| Product sales | 5,067 | 5,467 | 5,796 | 5,516 | 5,607 | 5,200 | 5,681 | 5,455 | 5,540 | 5,001 | 5,837 | 6,402 | 7,046 | 6,377 | 7,216 | 7,405 | 7,651 | 7,681 | 8,409 | 8,211 | 8,126 | 7,405 | |||||||
| Accounts receivable, net of allowances | 3,194 | 3,907 | 3,582 | 3,315 | 3,396 | 3,283 | 3,327 | 3,465 | 3,541 | 3,775 | 3,851 | 4,122 | 4,478 | 4,034 | 4,514 | 5,075 | 5,752 | 6,163 | 5,854 | 6,105 | 5,331 | 4,835 | |||||||
| Short-term Activity Ratio | |||||||||||||||||||||||||||||
| Receivables turnover1 | 6.84 | 5.73 | 6.18 | 6.64 | 6.46 | 6.66 | 6.52 | 6.30 | 6.43 | 6.43 | 6.66 | 6.56 | 6.26 | 7.10 | 6.64 | 6.14 | 5.55 | 5.26 | 5.49 | — | — | — | |||||||
| Benchmarks | |||||||||||||||||||||||||||||
| Receivables Turnover, Competitors2 | |||||||||||||||||||||||||||||
| Abbott Laboratories | 6.12 | 6.06 | 5.88 | 5.75 | 5.58 | 5.75 | 5.90 | 5.77 | 5.70 | 5.31 | 5.22 | 5.24 | 5.10 | 4.95 | 6.42 | 6.24 | 5.76 | 5.95 | 5.97 | — | — | — | |||||||
| AbbVie Inc. | 4.34 | 5.35 | 6.13 | 5.94 | 5.95 | 5.75 | 6.08 | 5.57 | 5.34 | 5.07 | 5.55 | 5.58 | 5.50 | 5.61 | 5.39 | 5.05 | 4.90 | 5.00 | 4.83 | — | — | — | |||||||
| Amgen Inc. | 4.31 | 4.55 | 5.47 | 6.19 | 5.89 | 5.96 | 6.29 | 6.42 | 6.29 | 6.04 | 6.73 | 6.43 | 6.17 | 6.73 | 6.92 | 6.77 | 7.00 | 6.92 | 6.99 | — | — | — | |||||||
| Biogen Inc. | 5.40 | 5.55 | 6.05 | 5.83 | 5.70 | 5.29 | 5.56 | 5.34 | 5.44 | 5.41 | 5.79 | 6.47 | 6.17 | 6.59 | 6.81 | 6.64 | 7.42 | 6.68 | 7.49 | — | — | — | |||||||
| Eli Lilly & Co. | 4.75 | 4.52 | 4.91 | 5.10 | 5.04 | 5.70 | 4.68 | 5.00 | 4.95 | 5.19 | 5.03 | 5.11 | 5.06 | 5.37 | 5.27 | 5.41 | 5.22 | 5.57 | 5.68 | — | — | — | |||||||
| Illumina Inc. | 8.70 | 7.53 | 6.18 | 6.39 | 7.24 | 7.43 | 6.48 | 7.49 | 7.86 | 7.34 | 6.70 | 6.77 | 6.68 | 6.59 | 6.29 | 6.21 | 6.21 | 5.60 | 5.76 | — | — | — | |||||||
| Johnson & Johnson | 5.50 | 5.56 | 5.67 | 5.52 | 5.55 | 5.78 | 5.79 | 5.79 | 5.72 | 5.56 | 5.67 | 5.65 | 5.46 | 5.87 | 6.14 | 6.07 | 5.88 | 6.15 | 6.53 | — | — | — | |||||||
| Merck & Co. Inc. | 6.23 | 5.88 | 6.91 | 5.45 | 5.57 | 5.66 | 5.98 | 5.66 | 5.66 | 5.62 | 5.84 | 5.19 | 5.38 | 5.65 | 5.67 | 5.42 | 5.70 | 5.75 | 6.09 | — | — | — | |||||||
| Pfizer Inc. | 5.39 | 5.13 | 5.93 | 5.62 | 5.48 | 5.61 | 6.68 | 5.32 | 5.39 | 5.57 | 6.39 | 5.25 | 5.52 | 5.92 | 6.42 | 5.41 | 5.72 | 5.65 | 5.97 | — | — | — | |||||||
| Regeneron Pharmaceuticals Inc. | 2.51 | 2.41 | 2.30 | 2.29 | 2.31 | 2.44 | 2.38 | 2.39 | 2.56 | 2.51 | 2.42 | 2.35 | 2.47 | 2.55 | 2.49 | 2.42 | 2.17 | 2.02 | 2.33 | — | — | — | |||||||
| Vertex Pharmaceuticals Inc. | 6.82 | 5.70 | 6.57 | 8.16 | 7.43 | 7.45 | 7.44 | 7.45 | 6.67 | 7.38 | 8.85 | 8.71 | 8.60 | 9.71 | 8.47 | 9.12 | 8.22 | 7.10 | 5.81 | — | — | — | |||||||
| Zoetis Inc. | 6.44 | 6.57 | 5.76 | 5.97 | 6.08 | 6.10 | 5.62 | 6.16 | 5.74 | 5.77 | 5.32 | 5.08 | 5.15 | 5.20 | 5.35 | 5.34 | 5.47 | 5.31 | 5.09 | — | — | — | |||||||
Based on: 10-Q (filing date: 2020-08-06), 10-Q (filing date: 2020-05-06), 10-K (filing date: 2020-02-25), 10-Q (filing date: 2019-11-05), 10-Q (filing date: 2019-08-06), 10-Q (filing date: 2019-05-08), 10-K (filing date: 2019-02-26), 10-Q (filing date: 2018-11-06), 10-Q (filing date: 2018-08-06), 10-Q (filing date: 2018-05-09), 10-K (filing date: 2018-02-27), 10-Q (filing date: 2017-11-07), 10-Q (filing date: 2017-08-07), 10-Q (filing date: 2017-05-10), 10-K (filing date: 2017-02-27), 10-Q (filing date: 2016-11-07), 10-Q (filing date: 2016-08-05), 10-Q (filing date: 2016-05-06), 10-K (filing date: 2016-02-24), 10-Q (filing date: 2015-11-04), 10-Q (filing date: 2015-08-05), 10-Q (filing date: 2015-05-08).
1 Q2 2020 Calculation
Receivables turnover
= (Product salesQ2 2020
+ Product salesQ1 2020
+ Product salesQ4 2019
+ Product salesQ3 2019)
÷ Accounts receivable, net of allowances
= (5,067 + 5,467 + 5,796 + 5,516)
÷ 3,194 = 6.84
2 Click competitor name to see calculations.
| Short-term activity ratio | Description | The company |
|---|---|---|
| Receivables turnover | An activity ratio equal to revenue divided by receivables. | Gilead Sciences Inc.’s receivables turnover ratio deteriorated from Q4 2019 to Q1 2020 but then improved from Q1 2020 to Q2 2020 exceeding Q4 2019 level. |
Payables Turnover
Gilead Sciences Inc., payables turnover calculation (quarterly data)
| Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||||||
| Cost of goods sold | 1,064 | 969 | 1,683 | 1,035 | 1,000 | 957 | 1,570 | 1,086 | 1,196 | 1,001 | 1,256 | 1,032 | 1,126 | 957 | 1,075 | 1,129 | 864 | 1,193 | 1,062 | 1,064 | 998 | 882 | |||||||
| Accounts payable | 532 | 590 | 713 | 632 | 617 | 577 | 790 | 580 | 623 | 711 | 814 | 696 | 819 | 944 | 1,206 | 1,052 | 1,122 | 945 | 1,178 | 1,239 | 1,571 | 1,011 | |||||||
| Short-term Activity Ratio | |||||||||||||||||||||||||||||
| Payables turnover1 | 8.93 | 7.94 | 6.56 | 7.22 | 7.48 | 8.33 | 6.14 | 7.83 | 7.20 | 6.21 | 5.37 | 6.02 | 5.23 | 4.26 | 3.53 | 4.04 | 3.73 | 4.57 | 3.40 | — | — | — | |||||||
| Benchmarks | |||||||||||||||||||||||||||||
| Payables Turnover, Competitors2 | |||||||||||||||||||||||||||||
| Abbott Laboratories | 4.00 | 4.20 | 4.07 | 4.29 | 3.97 | 4.20 | 4.27 | 4.68 | 4.98 | 4.99 | 5.14 | 6.13 | 6.49 | 6.70 | 7.66 | 8.49 | 7.70 | 8.36 | 8.09 | — | — | — | |||||||
| Amgen Inc. | 4.60 | 3.60 | 3.18 | 4.18 | 4.20 | 3.86 | 3.40 | 3.90 | 3.92 | 3.69 | 3.01 | 4.64 | 4.66 | 4.59 | 4.54 | 5.05 | 4.80 | 5.15 | 4.38 | — | — | — | |||||||
| Biogen Inc. | 4.54 | 4.65 | 3.68 | 5.22 | 5.38 | 5.22 | 4.90 | 5.37 | 5.91 | 4.89 | 4.12 | 5.02 | 4.68 | 4.90 | 5.28 | 5.23 | 5.87 | 4.57 | 4.64 | — | — | — | |||||||
| Bristol-Myers Squibb Co. | 3.72 | 3.22 | 3.30 | 3.89 | 3.58 | 3.44 | 3.46 | 3.68 | 3.45 | 3.70 | 2.70 | 3.40 | 3.55 | 3.43 | 2.97 | 3.21 | 2.86 | 2.67 | 2.50 | — | — | — | |||||||
| Eli Lilly & Co. | 3.92 | 3.97 | 3.36 | 4.51 | 4.52 | 5.13 | 4.55 | 5.04 | 4.91 | 4.98 | 4.30 | 4.93 | 4.57 | 4.64 | 4.19 | 4.80 | 4.48 | 4.49 | 3.76 | — | — | — | |||||||
| Illumina Inc. | 7.36 | 8.11 | 7.22 | 7.44 | 7.63 | 7.67 | 5.61 | 6.35 | 6.49 | 6.23 | 5.79 | 5.63 | 4.79 | 5.54 | 5.31 | 5.32 | 2.77 | 4.41 | 4.82 | — | — | — | |||||||
| Johnson & Johnson | 4.09 | 3.78 | 3.23 | 3.66 | 3.92 | 3.91 | 3.59 | 3.91 | 4.25 | 4.13 | 3.47 | 3.70 | 3.62 | 3.57 | 3.13 | 3.65 | 3.56 | 3.62 | 3.23 | — | — | — | |||||||
| Merck & Co. Inc. | 4.10 | 4.02 | 3.78 | 4.29 | 4.25 | 4.43 | 4.07 | 4.41 | 4.39 | 4.09 | 4.12 | 4.85 | 4.37 | 5.37 | 4.95 | 5.81 | 5.87 | 6.67 | 5.90 | — | — | — | |||||||
| Pfizer Inc. | 2.55 | 2.56 | 2.42 | 2.71 | 2.69 | 2.68 | 2.41 | 2.66 | 2.76 | 2.92 | 2.41 | 3.22 | 3.33 | 3.52 | 2.72 | 3.60 | 3.57 | 3.41 | 2.67 | — | — | — | |||||||
| Regeneron Pharmaceuticals Inc. | 1.07 | 1.06 | 0.87 | 0.89 | 0.87 | 0.76 | 0.82 | 1.10 | 1.19 | 1.01 | 1.14 | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Vertex Pharmaceuticals Inc. | 6.54 | 6.11 | 6.25 | 5.24 | 6.03 | 5.26 | 3.69 | 4.03 | 4.01 | 4.05 | 3.72 | 3.26 | 3.06 | 3.27 | 3.42 | 4.19 | 3.73 | 2.17 | 1.66 | — | — | — | |||||||
| Zoetis Inc. | 5.73 | 7.29 | 6.62 | 7.06 | 6.90 | 8.43 | 6.11 | 7.66 | 7.77 | 8.20 | 6.80 | 8.38 | 8.85 | 7.45 | 6.29 | 7.03 | 7.61 | 8.25 | 5.93 | — | — | — | |||||||
Based on: 10-Q (filing date: 2020-08-06), 10-Q (filing date: 2020-05-06), 10-K (filing date: 2020-02-25), 10-Q (filing date: 2019-11-05), 10-Q (filing date: 2019-08-06), 10-Q (filing date: 2019-05-08), 10-K (filing date: 2019-02-26), 10-Q (filing date: 2018-11-06), 10-Q (filing date: 2018-08-06), 10-Q (filing date: 2018-05-09), 10-K (filing date: 2018-02-27), 10-Q (filing date: 2017-11-07), 10-Q (filing date: 2017-08-07), 10-Q (filing date: 2017-05-10), 10-K (filing date: 2017-02-27), 10-Q (filing date: 2016-11-07), 10-Q (filing date: 2016-08-05), 10-Q (filing date: 2016-05-06), 10-K (filing date: 2016-02-24), 10-Q (filing date: 2015-11-04), 10-Q (filing date: 2015-08-05), 10-Q (filing date: 2015-05-08).
1 Q2 2020 Calculation
Payables turnover
= (Cost of goods soldQ2 2020
+ Cost of goods soldQ1 2020
+ Cost of goods soldQ4 2019
+ Cost of goods soldQ3 2019)
÷ Accounts payable
= (1,064 + 969 + 1,683 + 1,035)
÷ 532 = 8.93
2 Click competitor name to see calculations.
| Short-term activity ratio | Description | The company |
|---|---|---|
| Payables turnover | An activity ratio calculated as cost of goods sold divided by payables. | Gilead Sciences Inc.’s payables turnover ratio increased from Q4 2019 to Q1 2020 and from Q1 2020 to Q2 2020. |
Working Capital Turnover
Gilead Sciences Inc., working capital turnover calculation (quarterly data)
| Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||||||
| Current assets | 24,643 | 26,950 | 30,296 | 28,361 | 33,727 | 34,024 | 35,836 | 34,918 | 32,728 | 30,258 | 31,823 | 35,317 | 28,592 | 21,424 | 20,445 | 21,425 | 18,353 | 19,267 | 24,763 | 25,910 | 18,093 | 20,062 | |||||||
| Less: Current liabilities | 10,564 | 8,879 | 9,759 | 9,567 | 8,961 | 9,397 | 10,605 | 10,116 | 10,912 | 10,670 | 11,635 | 9,597 | 8,492 | 8,282 | 9,219 | 11,073 | 10,444 | 10,910 | 9,891 | 9,360 | 8,925 | 7,428 | |||||||
| Working capital | 14,079 | 18,071 | 20,537 | 18,794 | 24,766 | 24,627 | 25,231 | 24,802 | 21,816 | 19,588 | 20,188 | 25,720 | 20,100 | 13,142 | 11,226 | 10,352 | 7,909 | 8,357 | 14,872 | 16,550 | 9,168 | 12,634 | |||||||
| Product sales | 5,067 | 5,467 | 5,796 | 5,516 | 5,607 | 5,200 | 5,681 | 5,455 | 5,540 | 5,001 | 5,837 | 6,402 | 7,046 | 6,377 | 7,216 | 7,405 | 7,651 | 7,681 | 8,409 | 8,211 | 8,126 | 7,405 | |||||||
| Short-term Activity Ratio | |||||||||||||||||||||||||||||
| Working capital turnover1 | 1.55 | 1.24 | 1.08 | 1.17 | 0.89 | 0.89 | 0.86 | 0.88 | 1.04 | 1.24 | 1.27 | 1.05 | 1.40 | 2.18 | 2.67 | 3.01 | 4.04 | 3.88 | 2.16 | — | — | — | |||||||
| Benchmarks | |||||||||||||||||||||||||||||
| Working Capital Turnover, Competitors2 | |||||||||||||||||||||||||||||
| Abbott Laboratories | 5.02 | 6.84 | 6.64 | 5.57 | 5.04 | 5.80 | 5.44 | 5.61 | 5.72 | 4.78 | 2.44 | 1.87 | 1.79 | 1.76 | 1.04 | 4.45 | 4.76 | 5.08 | 4.11 | — | — | — | |||||||
| AbbVie Inc. | — | 0.97 | 0.98 | 12.30 | — | 64.14 | — | 10.46 | — | 8.75 | 6.16 | 4.62 | 5.68 | 3.91 | 4.00 | 3.51 | 3.29 | 3.99 | 4.22 | — | — | — | |||||||
| Amgen Inc. | 1.87 | 3.27 | 3.96 | 1.10 | 1.11 | 1.00 | 0.93 | 0.85 | 0.82 | 0.73 | 0.54 | 0.53 | 0.54 | 0.61 | 0.63 | 0.61 | 0.67 | 0.63 | 0.70 | — | — | — | |||||||
| Biogen Inc. | 2.28 | 3.44 | 3.23 | 2.81 | 2.38 | 1.91 | 2.51 | 1.94 | 2.48 | 1.49 | 2.30 | 2.46 | 2.70 | 2.56 | 1.85 | 1.74 | 1.95 | 2.11 | 2.23 | — | — | — | |||||||
| Bristol-Myers Squibb Co. | 3.09 | 2.38 | 2.28 | 0.78 | 0.82 | 2.71 | 3.32 | 4.04 | 5.09 | 3.91 | 3.64 | 3.39 | 3.52 | 3.58 | 3.64 | 3.98 | 3.58 | 4.13 | 5.86 | — | — | — | |||||||
| Eli Lilly & Co. | 8.85 | 16.68 | 11.54 | 12.35 | 14.53 | 17.59 | 2.84 | 2.46 | 4.52 | 4.95 | 4.90 | 4.72 | 4.94 | 8.54 | 5.16 | 4.08 | 4.50 | 4.61 | 4.59 | — | — | — | |||||||
| Illumina Inc. | 1.09 | 1.09 | 0.94 | 0.96 | 0.96 | 1.03 | 1.24 | 1.28 | 1.46 | 1.46 | 1.23 | 1.21 | 1.27 | 1.35 | 1.49 | 1.44 | 1.48 | 1.41 | 1.49 | — | — | — | |||||||
| Johnson & Johnson | 8.83 | 7.85 | 8.81 | 8.91 | 7.79 | 6.34 | 5.51 | 4.12 | 4.49 | 5.02 | 6.09 | 7.42 | 7.31 | 1.89 | 1.86 | 1.79 | 1.58 | 1.73 | 2.16 | — | — | — | |||||||
| Merck & Co. Inc. | 6.59 | 17.87 | 8.90 | 8.42 | 10.53 | 6.33 | 11.53 | 5.06 | 6.95 | 5.72 | 6.52 | 4.71 | 4.25 | 3.41 | 2.97 | 2.87 | 3.03 | 3.52 | 3.74 | — | — | — | |||||||
| Pfizer Inc. | 3.59 | 59.74 | — | — | 3.57 | 3.39 | 2.97 | 4.25 | 10.34 | 7.05 | 4.90 | 4.35 | 5.69 | 4.78 | 6.74 | 14.23 | 4.45 | 4.06 | 3.39 | — | — | — | |||||||
| Regeneron Pharmaceuticals Inc. | 1.20 | 0.75 | 0.86 | 0.87 | 0.90 | 0.78 | 0.82 | 0.93 | 1.13 | 1.17 | 1.16 | 1.20 | 1.24 | 1.45 | 1.72 | 1.27 | 1.38 | 1.32 | 1.28 | — | — | — | |||||||
| Vertex Pharmaceuticals Inc. | 1.10 | 1.23 | 1.19 | 1.07 | 1.00 | 1.06 | 1.12 | 1.05 | 1.06 | 1.09 | 1.35 | 1.42 | 1.37 | 1.46 | 1.64 | 2.13 | 1.87 | 1.52 | 1.15 | — | — | — | |||||||
| Zoetis Inc. | 1.42 | 2.08 | 2.13 | 1.72 | 1.77 | 1.79 | 1.83 | 1.86 | 1.71 | 1.67 | 1.70 | 1.63 | 2.79 | 3.00 | 2.15 | 2.10 | 2.12 | 2.25 | 2.33 | — | — | — | |||||||
Based on: 10-Q (filing date: 2020-08-06), 10-Q (filing date: 2020-05-06), 10-K (filing date: 2020-02-25), 10-Q (filing date: 2019-11-05), 10-Q (filing date: 2019-08-06), 10-Q (filing date: 2019-05-08), 10-K (filing date: 2019-02-26), 10-Q (filing date: 2018-11-06), 10-Q (filing date: 2018-08-06), 10-Q (filing date: 2018-05-09), 10-K (filing date: 2018-02-27), 10-Q (filing date: 2017-11-07), 10-Q (filing date: 2017-08-07), 10-Q (filing date: 2017-05-10), 10-K (filing date: 2017-02-27), 10-Q (filing date: 2016-11-07), 10-Q (filing date: 2016-08-05), 10-Q (filing date: 2016-05-06), 10-K (filing date: 2016-02-24), 10-Q (filing date: 2015-11-04), 10-Q (filing date: 2015-08-05), 10-Q (filing date: 2015-05-08).
1 Q2 2020 Calculation
Working capital turnover
= (Product salesQ2 2020
+ Product salesQ1 2020
+ Product salesQ4 2019
+ Product salesQ3 2019)
÷ Working capital
= (5,067 + 5,467 + 5,796 + 5,516)
÷ 14,079 = 1.55
2 Click competitor name to see calculations.
| Short-term activity ratio | Description | The company |
|---|---|---|
| Working capital turnover | An activity ratio calculated as revenue divided by working capital. | Gilead Sciences Inc.’s working capital turnover ratio improved from Q4 2019 to Q1 2020 and from Q1 2020 to Q2 2020. |
Average Inventory Processing Period
Gilead Sciences Inc., average inventory processing period calculation (quarterly data)
| Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | |||||||||||||||||||||||||||||
| Inventory turnover | 4.52 | 4.75 | 5.07 | 5.17 | 5.22 | 5.36 | 5.96 | 5.56 | 5.22 | 4.99 | 5.46 | 3.66 | 3.04 | 2.73 | 2.68 | 2.24 | 2.25 | 2.30 | 2.05 | — | — | — | |||||||
| Short-term Activity Ratio (no. days) | |||||||||||||||||||||||||||||
| Average inventory processing period1 | 81 | 77 | 72 | 71 | 70 | 68 | 61 | 66 | 70 | 73 | 67 | 100 | 120 | 134 | 136 | 163 | 162 | 159 | 178 | — | — | — | |||||||
| Benchmarks (no. days) | |||||||||||||||||||||||||||||
| Average Inventory Processing Period, Competitors2 | |||||||||||||||||||||||||||||
| Abbott Laboratories | 142 | 125 | 119 | 123 | 124 | 116 | 109 | 108 | 109 | 113 | 107 | 112 | 122 | 147 | 98 | 107 | 116 | 115 | 108 | — | — | — | |||||||
| AbbVie Inc. | 155 | 88 | 89 | 94 | 94 | 83 | 76 | 82 | 74 | 86 | 83 | 103 | 93 | 86 | 90 | 103 | 118 | 133 | 139 | — | — | — | |||||||
| Amgen Inc. | 265 | 279 | 300 | 282 | 276 | 261 | 262 | 271 | 278 | 268 | 254 | 262 | 263 | 253 | 241 | 235 | 234 | 223 | 210 | — | — | — | |||||||
| Biogen Inc. | 200 | 173 | 150 | 137 | 140 | 143 | 187 | 182 | 195 | 192 | 202 | 245 | 221 | 217 | 247 | 257 | 274 | 284 | 263 | — | — | — | |||||||
| Bristol-Myers Squibb Co. | 82 | 105 | 194 | 59 | 67 | 69 | 67 | 72 | 70 | 70 | 70 | 79 | 81 | 98 | 92 | 120 | 122 | 119 | 114 | — | — | — | |||||||
| Eli Lilly & Co. | 247 | 236 | 247 | 225 | 214 | 186 | 233 | 233 | 235 | 268 | 268 | 272 | 276 | 260 | 230 | 254 | 253 | 264 | 250 | — | — | — | |||||||
| Illumina Inc. | 160 | 133 | 122 | 143 | 144 | 143 | 136 | 138 | 137 | 136 | 131 | 134 | 134 | 139 | 150 | 160 | 164 | 154 | 147 | — | — | — | |||||||
| Johnson & Johnson | 124 | 116 | 119 | 122 | 125 | 122 | 116 | 116 | 116 | 124 | 126 | 147 | 159 | 149 | 137 | 142 | 144 | 138 | 136 | — | — | — | |||||||
| Merck & Co. Inc. | 156 | 148 | 155 | 156 | 160 | 156 | 147 | 145 | 142 | 152 | 146 | 151 | 154 | 141 | 128 | 133 | 130 | 125 | 115 | — | — | — | |||||||
| Pfizer Inc. | 317 | 302 | 296 | 281 | 279 | 264 | 244 | 261 | 254 | 262 | 246 | 258 | 242 | 227 | 201 | 219 | 238 | 259 | 284 | — | — | — | |||||||
| Regeneron Pharmaceuticals Inc. | 1,476 | 1,460 | 1,426 | 1,648 | 2,260 | 2,429 | 2,334 | 2,011 | 1,659 | 1,423 | 1,309 | 1,205 | 1,138 | 963 | 749 | 570 | 446 | 398 | 360 | — | — | — | |||||||
| Vertex Pharmaceuticals Inc. | 121 | 111 | 112 | 122 | 112 | 115 | 111 | 122 | 126 | 143 | 148 | 142 | 145 | 145 | 135 | 123 | 127 | 142 | 168 | — | — | — | |||||||
| Zoetis Inc. | 301 | 280 | 258 | 262 | 256 | 251 | 266 | 288 | 290 | 296 | 293 | 305 | 310 | 326 | 329 | 337 | 326 | 308 | 308 | — | — | — | |||||||
Based on: 10-Q (filing date: 2020-08-06), 10-Q (filing date: 2020-05-06), 10-K (filing date: 2020-02-25), 10-Q (filing date: 2019-11-05), 10-Q (filing date: 2019-08-06), 10-Q (filing date: 2019-05-08), 10-K (filing date: 2019-02-26), 10-Q (filing date: 2018-11-06), 10-Q (filing date: 2018-08-06), 10-Q (filing date: 2018-05-09), 10-K (filing date: 2018-02-27), 10-Q (filing date: 2017-11-07), 10-Q (filing date: 2017-08-07), 10-Q (filing date: 2017-05-10), 10-K (filing date: 2017-02-27), 10-Q (filing date: 2016-11-07), 10-Q (filing date: 2016-08-05), 10-Q (filing date: 2016-05-06), 10-K (filing date: 2016-02-24), 10-Q (filing date: 2015-11-04), 10-Q (filing date: 2015-08-05), 10-Q (filing date: 2015-05-08).
1 Q2 2020 Calculation
Average inventory processing period = 365 ÷ Inventory turnover
= 365 ÷ 4.52 = 81
2 Click competitor name to see calculations.
| Short-term activity ratio | Description | The company |
|---|---|---|
| Average inventory processing period | An activity ratio equal to the number of days in the period divided by inventory turnover over the period. | Gilead Sciences Inc.’s number of days of inventory outstanding deteriorated from Q4 2019 to Q1 2020 and from Q1 2020 to Q2 2020. |
Average Receivable Collection Period
Gilead Sciences Inc., average receivable collection period calculation (quarterly data)
| Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | |||||||||||||||||||||||||||||
| Receivables turnover | 6.84 | 5.73 | 6.18 | 6.64 | 6.46 | 6.66 | 6.52 | 6.30 | 6.43 | 6.43 | 6.66 | 6.56 | 6.26 | 7.10 | 6.64 | 6.14 | 5.55 | 5.26 | 5.49 | — | — | — | |||||||
| Short-term Activity Ratio (no. days) | |||||||||||||||||||||||||||||
| Average receivable collection period1 | 53 | 64 | 59 | 55 | 56 | 55 | 56 | 58 | 57 | 57 | 55 | 56 | 58 | 51 | 55 | 59 | 66 | 69 | 66 | — | — | — | |||||||
| Benchmarks (no. days) | |||||||||||||||||||||||||||||
| Average Receivable Collection Period, Competitors2 | |||||||||||||||||||||||||||||
| Abbott Laboratories | 60 | 60 | 62 | 63 | 65 | 64 | 62 | 63 | 64 | 69 | 70 | 70 | 72 | 74 | 57 | 59 | 63 | 61 | 61 | — | — | — | |||||||
| AbbVie Inc. | 84 | 68 | 60 | 61 | 61 | 64 | 60 | 66 | 68 | 72 | 66 | 65 | 66 | 65 | 68 | 72 | 74 | 73 | 76 | — | — | — | |||||||
| Amgen Inc. | 85 | 80 | 67 | 59 | 62 | 61 | 58 | 57 | 58 | 60 | 54 | 57 | 59 | 54 | 53 | 54 | 52 | 53 | 52 | — | — | — | |||||||
| Biogen Inc. | 68 | 66 | 60 | 63 | 64 | 69 | 66 | 68 | 67 | 67 | 63 | 56 | 59 | 55 | 54 | 55 | 49 | 55 | 49 | — | — | — | |||||||
| Eli Lilly & Co. | 77 | 81 | 74 | 72 | 72 | 64 | 78 | 73 | 74 | 70 | 73 | 71 | 72 | 68 | 69 | 67 | 70 | 66 | 64 | — | — | — | |||||||
| Illumina Inc. | 42 | 48 | 59 | 57 | 50 | 49 | 56 | 49 | 46 | 50 | 55 | 54 | 55 | 55 | 58 | 59 | 59 | 65 | 63 | — | — | — | |||||||
| Johnson & Johnson | 66 | 66 | 64 | 66 | 66 | 63 | 63 | 63 | 64 | 66 | 64 | 65 | 67 | 62 | 59 | 60 | 62 | 59 | 56 | — | — | — | |||||||
| Merck & Co. Inc. | 59 | 62 | 53 | 67 | 66 | 64 | 61 | 64 | 64 | 65 | 63 | 70 | 68 | 65 | 64 | 67 | 64 | 63 | 60 | — | — | — | |||||||
| Pfizer Inc. | 68 | 71 | 62 | 65 | 67 | 65 | 55 | 69 | 68 | 65 | 57 | 70 | 66 | 62 | 57 | 67 | 64 | 65 | 61 | — | — | — | |||||||
| Regeneron Pharmaceuticals Inc. | 146 | 152 | 159 | 159 | 158 | 149 | 153 | 152 | 143 | 145 | 151 | 155 | 148 | 143 | 147 | 151 | 168 | 181 | 156 | — | — | — | |||||||
| Vertex Pharmaceuticals Inc. | 53 | 64 | 56 | 45 | 49 | 49 | 49 | 49 | 55 | 49 | 41 | 42 | 42 | 38 | 43 | 40 | 44 | 51 | 63 | — | — | — | |||||||
| Zoetis Inc. | 57 | 56 | 63 | 61 | 60 | 60 | 65 | 59 | 64 | 63 | 69 | 72 | 71 | 70 | 68 | 68 | 67 | 69 | 72 | — | — | — | |||||||
Based on: 10-Q (filing date: 2020-08-06), 10-Q (filing date: 2020-05-06), 10-K (filing date: 2020-02-25), 10-Q (filing date: 2019-11-05), 10-Q (filing date: 2019-08-06), 10-Q (filing date: 2019-05-08), 10-K (filing date: 2019-02-26), 10-Q (filing date: 2018-11-06), 10-Q (filing date: 2018-08-06), 10-Q (filing date: 2018-05-09), 10-K (filing date: 2018-02-27), 10-Q (filing date: 2017-11-07), 10-Q (filing date: 2017-08-07), 10-Q (filing date: 2017-05-10), 10-K (filing date: 2017-02-27), 10-Q (filing date: 2016-11-07), 10-Q (filing date: 2016-08-05), 10-Q (filing date: 2016-05-06), 10-K (filing date: 2016-02-24), 10-Q (filing date: 2015-11-04), 10-Q (filing date: 2015-08-05), 10-Q (filing date: 2015-05-08).
1 Q2 2020 Calculation
Average receivable collection period = 365 ÷ Receivables turnover
= 365 ÷ 6.84 = 53
2 Click competitor name to see calculations.
| Short-term activity ratio | Description | The company |
|---|---|---|
| Average receivable collection period | An activity ratio equal to the number of days in the period divided by receivables turnover. | Gilead Sciences Inc.’s number of days of receivables outstanding deteriorated from Q4 2019 to Q1 2020 but then improved from Q1 2020 to Q2 2020 exceeding Q4 2019 level. |
Operating Cycle
Gilead Sciences Inc., operating cycle calculation (quarterly data)
No. days
| Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | |||||||||||||||||||||||||||||
| Average inventory processing period | 81 | 77 | 72 | 71 | 70 | 68 | 61 | 66 | 70 | 73 | 67 | 100 | 120 | 134 | 136 | 163 | 162 | 159 | 178 | — | — | — | |||||||
| Average receivable collection period | 53 | 64 | 59 | 55 | 56 | 55 | 56 | 58 | 57 | 57 | 55 | 56 | 58 | 51 | 55 | 59 | 66 | 69 | 66 | — | — | — | |||||||
| Short-term Activity Ratio | |||||||||||||||||||||||||||||
| Operating cycle1 | 134 | 141 | 131 | 126 | 126 | 123 | 117 | 124 | 127 | 130 | 122 | 156 | 178 | 185 | 191 | 222 | 228 | 228 | 244 | — | — | — | |||||||
| Benchmarks | |||||||||||||||||||||||||||||
| Operating Cycle, Competitors2 | |||||||||||||||||||||||||||||
| Abbott Laboratories | 202 | 185 | 181 | 186 | 189 | 180 | 171 | 171 | 173 | 182 | 177 | 182 | 194 | 221 | 155 | 166 | 179 | 176 | 169 | — | — | — | |||||||
| AbbVie Inc. | 239 | 156 | 149 | 155 | 155 | 147 | 136 | 148 | 142 | 158 | 149 | 168 | 159 | 151 | 158 | 175 | 192 | 206 | 215 | — | — | — | |||||||
| Amgen Inc. | 350 | 359 | 367 | 341 | 338 | 322 | 320 | 328 | 336 | 328 | 308 | 319 | 322 | 307 | 294 | 289 | 286 | 276 | 262 | — | — | — | |||||||
| Biogen Inc. | 268 | 239 | 210 | 200 | 204 | 212 | 253 | 250 | 262 | 259 | 265 | 301 | 280 | 272 | 301 | 312 | 323 | 339 | 312 | — | — | — | |||||||
| Eli Lilly & Co. | 324 | 317 | 321 | 297 | 286 | 250 | 311 | 306 | 309 | 338 | 341 | 343 | 348 | 328 | 299 | 321 | 323 | 330 | 314 | — | — | — | |||||||
| Illumina Inc. | 202 | 181 | 181 | 200 | 194 | 192 | 192 | 187 | 183 | 186 | 186 | 188 | 189 | 194 | 208 | 219 | 223 | 219 | 210 | — | — | — | |||||||
| Johnson & Johnson | 190 | 182 | 183 | 188 | 191 | 185 | 179 | 179 | 180 | 190 | 190 | 212 | 226 | 211 | 196 | 202 | 206 | 197 | 192 | — | — | — | |||||||
| Merck & Co. Inc. | 215 | 210 | 208 | 223 | 226 | 220 | 208 | 209 | 206 | 217 | 209 | 221 | 222 | 206 | 192 | 200 | 194 | 188 | 175 | — | — | — | |||||||
| Pfizer Inc. | 385 | 373 | 358 | 346 | 346 | 329 | 299 | 330 | 322 | 327 | 303 | 328 | 308 | 289 | 258 | 286 | 302 | 324 | 345 | — | — | — | |||||||
| Regeneron Pharmaceuticals Inc. | 1,622 | 1,612 | 1,585 | 1,807 | 2,418 | 2,578 | 2,487 | 2,163 | 1,802 | 1,568 | 1,460 | 1,360 | 1,286 | 1,106 | 896 | 721 | 614 | 579 | 516 | — | — | — | |||||||
| Vertex Pharmaceuticals Inc. | 174 | 175 | 168 | 167 | 161 | 164 | 160 | 171 | 181 | 192 | 189 | 184 | 187 | 183 | 178 | 163 | 171 | 193 | 231 | — | — | — | |||||||
| Zoetis Inc. | 358 | 336 | 321 | 323 | 316 | 311 | 331 | 347 | 354 | 359 | 362 | 377 | 381 | 396 | 397 | 405 | 393 | 377 | 380 | — | — | — | |||||||
Based on: 10-Q (filing date: 2020-08-06), 10-Q (filing date: 2020-05-06), 10-K (filing date: 2020-02-25), 10-Q (filing date: 2019-11-05), 10-Q (filing date: 2019-08-06), 10-Q (filing date: 2019-05-08), 10-K (filing date: 2019-02-26), 10-Q (filing date: 2018-11-06), 10-Q (filing date: 2018-08-06), 10-Q (filing date: 2018-05-09), 10-K (filing date: 2018-02-27), 10-Q (filing date: 2017-11-07), 10-Q (filing date: 2017-08-07), 10-Q (filing date: 2017-05-10), 10-K (filing date: 2017-02-27), 10-Q (filing date: 2016-11-07), 10-Q (filing date: 2016-08-05), 10-Q (filing date: 2016-05-06), 10-K (filing date: 2016-02-24), 10-Q (filing date: 2015-11-04), 10-Q (filing date: 2015-08-05), 10-Q (filing date: 2015-05-08).
1 Q2 2020 Calculation
Operating cycle = Average inventory processing period + Average receivable collection period
= 81 + 53 = 134
2 Click competitor name to see calculations.
| Short-term activity ratio | Description | The company |
|---|---|---|
| Operating cycle | Equal to average inventory processing period plus average receivables collection period. | Gilead Sciences Inc.’s operating cycle deteriorated from Q4 2019 to Q1 2020 but then improved from Q1 2020 to Q2 2020 not reaching Q4 2019 level. |
Average Payables Payment Period
Gilead Sciences Inc., average payables payment period calculation (quarterly data)
| Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | |||||||||||||||||||||||||||||
| Payables turnover | 8.93 | 7.94 | 6.56 | 7.22 | 7.48 | 8.33 | 6.14 | 7.83 | 7.20 | 6.21 | 5.37 | 6.02 | 5.23 | 4.26 | 3.53 | 4.04 | 3.73 | 4.57 | 3.40 | — | — | — | |||||||
| Short-term Activity Ratio (no. days) | |||||||||||||||||||||||||||||
| Average payables payment period1 | 41 | 46 | 56 | 51 | 49 | 44 | 59 | 47 | 51 | 59 | 68 | 61 | 70 | 86 | 103 | 90 | 98 | 80 | 107 | — | — | — | |||||||
| Benchmarks (no. days) | |||||||||||||||||||||||||||||
| Average Payables Payment Period, Competitors2 | |||||||||||||||||||||||||||||
| Abbott Laboratories | 91 | 87 | 90 | 85 | 92 | 87 | 85 | 78 | 73 | 73 | 71 | 60 | 56 | 54 | 48 | 43 | 47 | 44 | 45 | — | — | — | |||||||
| Amgen Inc. | 79 | 101 | 115 | 87 | 87 | 95 | 107 | 94 | 93 | 99 | 121 | 79 | 78 | 80 | 80 | 72 | 76 | 71 | 83 | — | — | — | |||||||
| Biogen Inc. | 80 | 79 | 99 | 70 | 68 | 70 | 74 | 68 | 62 | 75 | 89 | 73 | 78 | 74 | 69 | 70 | 62 | 80 | 79 | — | — | — | |||||||
| Bristol-Myers Squibb Co. | 98 | 113 | 110 | 94 | 102 | 106 | 105 | 99 | 106 | 99 | 135 | 107 | 103 | 106 | 123 | 114 | 127 | 137 | 146 | — | — | — | |||||||
| Eli Lilly & Co. | 93 | 92 | 109 | 81 | 81 | 71 | 80 | 72 | 74 | 73 | 85 | 74 | 80 | 79 | 87 | 76 | 81 | 81 | 97 | — | — | — | |||||||
| Illumina Inc. | 50 | 45 | 51 | 49 | 48 | 48 | 65 | 57 | 56 | 59 | 63 | 65 | 76 | 66 | 69 | 69 | 132 | 83 | 76 | — | — | — | |||||||
| Johnson & Johnson | 89 | 97 | 113 | 100 | 93 | 93 | 102 | 93 | 86 | 88 | 105 | 99 | 101 | 102 | 116 | 100 | 103 | 101 | 113 | — | — | — | |||||||
| Merck & Co. Inc. | 89 | 91 | 97 | 85 | 86 | 82 | 90 | 83 | 83 | 89 | 89 | 75 | 83 | 68 | 74 | 63 | 62 | 55 | 62 | — | — | — | |||||||
| Pfizer Inc. | 143 | 143 | 151 | 135 | 136 | 136 | 152 | 137 | 132 | 125 | 151 | 113 | 110 | 104 | 134 | 101 | 102 | 107 | 137 | — | — | — | |||||||
| Regeneron Pharmaceuticals Inc. | 342 | 343 | 421 | 411 | 419 | 481 | 442 | 333 | 307 | 360 | 321 | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Vertex Pharmaceuticals Inc. | 56 | 60 | 58 | 70 | 61 | 69 | 99 | 91 | 91 | 90 | 98 | 112 | 119 | 111 | 107 | 87 | 98 | 169 | 220 | — | — | — | |||||||
| Zoetis Inc. | 64 | 50 | 55 | 52 | 53 | 43 | 60 | 48 | 47 | 45 | 54 | 44 | 41 | 49 | 58 | 52 | 48 | 44 | 62 | — | — | — | |||||||
Based on: 10-Q (filing date: 2020-08-06), 10-Q (filing date: 2020-05-06), 10-K (filing date: 2020-02-25), 10-Q (filing date: 2019-11-05), 10-Q (filing date: 2019-08-06), 10-Q (filing date: 2019-05-08), 10-K (filing date: 2019-02-26), 10-Q (filing date: 2018-11-06), 10-Q (filing date: 2018-08-06), 10-Q (filing date: 2018-05-09), 10-K (filing date: 2018-02-27), 10-Q (filing date: 2017-11-07), 10-Q (filing date: 2017-08-07), 10-Q (filing date: 2017-05-10), 10-K (filing date: 2017-02-27), 10-Q (filing date: 2016-11-07), 10-Q (filing date: 2016-08-05), 10-Q (filing date: 2016-05-06), 10-K (filing date: 2016-02-24), 10-Q (filing date: 2015-11-04), 10-Q (filing date: 2015-08-05), 10-Q (filing date: 2015-05-08).
1 Q2 2020 Calculation
Average payables payment period = 365 ÷ Payables turnover
= 365 ÷ 8.93 = 41
2 Click competitor name to see calculations.
| Short-term activity ratio | Description | The company |
|---|---|---|
| Average payables payment period | An estimate of the average number of days it takes a company to pay its suppliers; equal to the number of days in the period divided by payables turnover ratio for the period. | Gilead Sciences Inc.’s number of days of payables outstanding decreased from Q4 2019 to Q1 2020 and from Q1 2020 to Q2 2020. |
Cash Conversion Cycle
Gilead Sciences Inc., cash conversion cycle calculation (quarterly data)
No. days
| Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | |||||||||||||||||||||||||||||
| Average inventory processing period | 81 | 77 | 72 | 71 | 70 | 68 | 61 | 66 | 70 | 73 | 67 | 100 | 120 | 134 | 136 | 163 | 162 | 159 | 178 | — | — | — | |||||||
| Average receivable collection period | 53 | 64 | 59 | 55 | 56 | 55 | 56 | 58 | 57 | 57 | 55 | 56 | 58 | 51 | 55 | 59 | 66 | 69 | 66 | — | — | — | |||||||
| Average payables payment period | 41 | 46 | 56 | 51 | 49 | 44 | 59 | 47 | 51 | 59 | 68 | 61 | 70 | 86 | 103 | 90 | 98 | 80 | 107 | — | — | — | |||||||
| Short-term Activity Ratio | |||||||||||||||||||||||||||||
| Cash conversion cycle1 | 93 | 95 | 75 | 75 | 77 | 79 | 58 | 77 | 76 | 71 | 54 | 95 | 108 | 99 | 88 | 132 | 130 | 148 | 137 | — | — | — | |||||||
| Benchmarks | |||||||||||||||||||||||||||||
| Cash Conversion Cycle, Competitors2 | |||||||||||||||||||||||||||||
| Abbott Laboratories | 111 | 98 | 91 | 101 | 97 | 93 | 86 | 93 | 100 | 109 | 106 | 122 | 138 | 167 | 107 | 123 | 132 | 132 | 124 | — | — | — | |||||||
| Amgen Inc. | 271 | 258 | 252 | 254 | 251 | 227 | 213 | 234 | 243 | 229 | 187 | 240 | 244 | 227 | 214 | 217 | 210 | 205 | 179 | — | — | — | |||||||
| Biogen Inc. | 188 | 160 | 111 | 130 | 136 | 142 | 179 | 182 | 200 | 184 | 176 | 228 | 202 | 198 | 232 | 242 | 261 | 259 | 233 | — | — | — | |||||||
| Eli Lilly & Co. | 231 | 225 | 212 | 216 | 205 | 179 | 231 | 234 | 235 | 265 | 256 | 269 | 268 | 249 | 212 | 245 | 242 | 249 | 217 | — | — | — | |||||||
| Illumina Inc. | 152 | 136 | 130 | 151 | 146 | 144 | 127 | 130 | 127 | 127 | 123 | 123 | 113 | 128 | 139 | 150 | 91 | 136 | 134 | — | — | — | |||||||
| Johnson & Johnson | 101 | 85 | 70 | 88 | 98 | 92 | 77 | 86 | 94 | 102 | 85 | 113 | 125 | 109 | 80 | 102 | 103 | 96 | 79 | — | — | — | |||||||
| Merck & Co. Inc. | 126 | 119 | 111 | 138 | 140 | 138 | 118 | 126 | 123 | 128 | 120 | 146 | 139 | 138 | 118 | 137 | 132 | 133 | 113 | — | — | — | |||||||
| Pfizer Inc. | 242 | 230 | 207 | 211 | 210 | 193 | 147 | 193 | 190 | 202 | 152 | 215 | 198 | 185 | 124 | 185 | 200 | 217 | 208 | — | — | — | |||||||
| Regeneron Pharmaceuticals Inc. | 1,280 | 1,269 | 1,164 | 1,396 | 1,999 | 2,097 | 2,045 | 1,830 | 1,495 | 1,208 | 1,139 | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Vertex Pharmaceuticals Inc. | 118 | 115 | 110 | 97 | 100 | 95 | 61 | 80 | 90 | 102 | 91 | 72 | 68 | 72 | 71 | 76 | 73 | 24 | 11 | — | — | — | |||||||
| Zoetis Inc. | 294 | 286 | 266 | 271 | 263 | 268 | 271 | 299 | 307 | 314 | 308 | 333 | 340 | 347 | 339 | 353 | 345 | 333 | 318 | — | — | — | |||||||
Based on: 10-Q (filing date: 2020-08-06), 10-Q (filing date: 2020-05-06), 10-K (filing date: 2020-02-25), 10-Q (filing date: 2019-11-05), 10-Q (filing date: 2019-08-06), 10-Q (filing date: 2019-05-08), 10-K (filing date: 2019-02-26), 10-Q (filing date: 2018-11-06), 10-Q (filing date: 2018-08-06), 10-Q (filing date: 2018-05-09), 10-K (filing date: 2018-02-27), 10-Q (filing date: 2017-11-07), 10-Q (filing date: 2017-08-07), 10-Q (filing date: 2017-05-10), 10-K (filing date: 2017-02-27), 10-Q (filing date: 2016-11-07), 10-Q (filing date: 2016-08-05), 10-Q (filing date: 2016-05-06), 10-K (filing date: 2016-02-24), 10-Q (filing date: 2015-11-04), 10-Q (filing date: 2015-08-05), 10-Q (filing date: 2015-05-08).
1 Q2 2020 Calculation
Cash conversion cycle = Average inventory processing period + Average receivable collection period – Average payables payment period
= 81 + 53 – 41 = 93
2 Click competitor name to see calculations.
| Short-term activity ratio | Description | The company |
|---|---|---|
| Cash conversion cycle | A financial metric that measures the length of time required for a company to convert cash invested in its operations to cash received as a result of its operations; equal to average inventory processing period plus average receivables collection period minus average payables payment period. | Gilead Sciences Inc.’s cash conversion cycle deteriorated from Q4 2019 to Q1 2020 but then slightly improved from Q1 2020 to Q2 2020. |